The Effect of Different Types of Progestin on Sleeping of Menopausal Women

NCT ID: NCT02086032

Last Updated: 2017-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators have found that sleeping disorder is an important problem in menopausal women.

There have been papers reporting the effect of hormonal therapy on sleeping, but fews have reported the effect of different progestogens on sleeping quality. There is a need for more in-depth study and more conclusive evidence about the progestins which have the most beneficial effects on sleeping disorders in menopausal women.

This study is going to collect the data from newly identified menopausal patients who are eligible for continuous estrogen-progestogen therapy for their climacteric treatment. The affects of the therapy will be monitored for 3 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

New patients who are eligible for hormonal therapy will be selected.

They will be allocated randomly into 2 different groups, each group being prescribed 1 of 2 regimens of hormonal therapy:

* 17 beta estradiol 1mg/day plus oral micronized progesterone 100mg/day
* 17 beta estradiol 1mg/day plus dydrogesterone 10mg/day Patients will have their sleeping quality accessed using the Pittsburgh sleep quality index(PSQI) at their 1st visit and once a month for 3 months. The first and third PSQI score will be analysed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menopausal and Postmenopausal Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

micronized progesterone

1 mg 17 beta-estradiol plus 100 mg micronized progesterone taken orally once a day for 3 months.

Group Type EXPERIMENTAL

1mg 17 beta-estradiol

Intervention Type DRUG

Comparing sleeping quality between micronized progesterone and dydrogesterone users.

micronized progesterone

Intervention Type DRUG

Comparing sleeping quality between micronised progesterone and dydrogesterone users

dydrogesterone

1mg 17 beta-estradiol plus 10 mg dydrogesterone taken orally once a day for 3 months.

Group Type EXPERIMENTAL

1mg 17 beta-estradiol

Intervention Type DRUG

Comparing sleeping quality between micronized progesterone and dydrogesterone users.

Dydrogesterone

Intervention Type DRUG

Comparing sleeping quality between micronised progesterone and dydrogesterone users.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1mg 17 beta-estradiol

Comparing sleeping quality between micronized progesterone and dydrogesterone users.

Intervention Type DRUG

Dydrogesterone

Comparing sleeping quality between micronised progesterone and dydrogesterone users.

Intervention Type DRUG

micronized progesterone

Comparing sleeping quality between micronised progesterone and dydrogesterone users

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Estrogen Duphaston Utrogestan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* new menopausal patients at Maharaj Nakorn Chiang Mai Hospital
* suitable for estrogen plus progesterone treatment

Exclusion Criteria

* contraindication for hormone replacement therapy
* recently used sleep enhancing medicine
* recently used psychotic medicine
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chiang Mai University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ekachai Leeangkoonsathian

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tawiwan Pantasri, MD

Role: PRINCIPAL_INVESTIGATOR

Faculty of Medicine, Chiang Mai University, Thailand

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Obstetrics and Gynecology department, Faculty of Medicine, Chiang Mai University

Muang, Chiang Mai, Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

References

Explore related publications, articles, or registry entries linked to this study.

Leeangkoonsathian E, Pantasri T, Chaovisitseree S, Morakot N. The effect of different progestogens on sleep in postmenopausal women: a randomized trial. Gynecol Endocrinol. 2017 Dec;33(12):933-936. doi: 10.1080/09513590.2017.1333094. Epub 2017 Jun 13.

Reference Type DERIVED
PMID: 28609128 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OBG-2556-02070

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sleep and Health Outcomes in Women With Heavy Menses
NCT05722444 ACTIVE_NOT_RECRUITING NA
Melatonin Effects on Luteinizing Hormone
NCT00288262 TERMINATED PHASE1/PHASE2
Sleep Quality and the Menstrual Cycle
NCT06906133 ACTIVE_NOT_RECRUITING